Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 2/20 | 0.30 |
| ▸ | AKT2 | P31751 | 2/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514025 | 0.86 | XIAP (0.37) | XIAPPTGS2MEN1KMT2AALDH1A1 | |
| SCHEMBL514026 | 0.86 | XIAP (0.37) | XIAPPTGS2MEN1KMT2AALDH1A1 | |
| SCHEMBL513693 | 0.86 | SYK (0.32) | PTGS2FABP4AKT1AKT2 | |
| SCHEMBL513990 | 0.86 | XIAP (0.33) | XIAPPTGS2FABP4 | |
| SCHEMBL513102 | 0.84 | FABP4 (0.33) | FABP4 | |
| SCHEMBL514802 | 0.83 | PTGDR2 (0.35) | PTGS2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL514234 | 0.83 | CDC7 (0.31) | — | |
| SCHEMBL513117 | 0.82 | ALDH1A1 (0.47) | XIAPMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL513116 | 0.82 | ALDH1A1 (0.47) | XIAPMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL515252 | 0.81 | AKT1 (0.37) | PTGS2MEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102605-A1 | INHIBITORS OF AKT ACTIVITY | LIANG PENG (CN) | 2013-04-25 | — | — | US | disclosed |
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | PIK3CA, G6PC1, PIK3C2B | XIAP 994/4885PTGS2 3234/4885FABP4 4044/4885 |
| US-20130102605-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, PIK3CD, AKT2 | XIAP 750/4885PTGS2 3473/4885FABP4 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.